Proteros Achieves Key Milestone in Janssen Lead Discovery Collaboration
Proteros biostructures GmbH announced it had achieved an important milestone in a lead discovery collaboration with Janssen Pharmaceutica NV triggering an undisclosed payment to Proteros.
Proteros has collaborated with Janssen for over a decade supporting numerous projects across all therapeutic areas. The objective of this oncology focused project was for Proteros to discover potent and selective small molecule inhibitor series against a novel protein target. Based on the establishment of a de novo X-ray crystallography system, HTS screening and biophysical assay technology of the novel target Proteros delivered multiple chemical series meeting stringent compound criteria.
Dr. Peter Reinemer, Chief Operating Officer for Proteros, stated: "We are very pleased to be Janssen's partner in one of their oncology discovery programs and that we have been able to deliver new compound classes for a challenging novel drug target."
Most read news
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Second quarter impacted by declines in glyphosate business - Group sales fall by 8.2 percent (Fx & portfolio adj.) to 11.044 billion euros
NIMH funds major schizophrenia project - Researchers to examine unexpected genetic variation in brain

A sprinkle of platinum nanoparticles onto graphene makes brain probes more sensitive

Molecular Devices acquires Cellesce - “This enabling technology will make over 100,000 compound primary screens with PDOs a reality and will accelerate industry adoption of organoids”
Successfully Treating Genetically Determined Autoimmune Enteritis
Urachal_cancer

Tiny microbes could brew big benefits for green biomanufacturing - The discovery could reduce greenhouse gas emissions from the manufacturing of fuels, drugs, and chemicals

Missed Connections
